SCHEMBL23387364

SCHEMBL23387364

CC(C)c1ccc(CC(=O)NC2CNC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.50
▸ CNR2 P34972 2/20 0.49
▸ KMT2A Q03164 3/20 0.47
▸ NLRP3 Q96P20 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ MEN1 O00255 2/20 0.45
▸ GRM7 Q14831 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ EPHX2 P34913 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ HDAC3 O15379 1/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HDAC7 Q8WUI4 1/20 0.43
▸ HDAC2 Q92769 1/20 0.43
▸ HDAC10 Q969S8 1/20 0.43
▸ HDAC11 Q96DB2 1/20 0.43
▸ HDAC8 Q9BY41 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21624693 0.89 LMNA (0.49) LMNACNR2KMT2ANLRP3POLB
SCHEMBL21424360 0.89 LMNA (0.49) LMNACNR2KMT2ANLRP3POLB
SCHEMBL21624691 0.89 LMNA (0.49) LMNACNR2KMT2ANLRP3POLB
SCHEMBL21624779 0.85 LMNA (0.55) LMNACNR2KMT2ANLRP3POLB
SCHEMBL27396501 0.82 POLB (0.70) LMNAKMT2APOLBMEN1NPC1
Hydrochloric Acid SCHEMBL30590270 0.79 LMNA (0.48) LMNACNR2KMT2ANLRP3POLB
SCHEMBL24342370 0.79 EPHX2 (0.65) KMT2APOLBMEN1GRM7EPHX2
SCHEMBL14924027 0.78 L3MBTL1 (0.55) LMNAKMT2APOLBMEN1NPC1
Acetic Acid SCHEMBL27676285 0.78 EPHX2 (0.59) KMT2APOLBMEN1EPHX2HDAC8
SCHEMBL20804092 0.78 LMNA (0.50) LMNAKMT2AMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220363667-A1 T-TYPE CALCIUM CHANNEL BLOCKER NIPPON CHEMIPHAR CO., LTD. (JP) 2022-11-17 — — US disclosed
US-20220226299-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS NIPPON CHEMIPHAR CO., LTD. (JP) 2022-07-21 — — US disclosed
EP-3950059-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS Nippon Chemiphar Co., Ltd. (JP) 2022-02-09 — — EP disclosed
EP-3825303-A1 T-TYPE CALCIUM CHANNEL BLOCKER Nippon Chemiphar Co., Ltd. (JP) 2021-05-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220363667-A1 T-TYPE CALCIUM CHANNEL BLOCKER CACNA1I, CACNA1G, CACNA1H LMNA 3066/4885CNR2 418/4885KMT2A 2926/4885
US-20220226299-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS TRPV3, CACNA1G, TRPV2 LMNA 3286/4885CNR2 164/4885KMT2A 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback